As part of our ongoing aim to bring you reports of new developments, we have added a review of a recent study update on the SHAMAL asthma study - Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab.
Independent commentary for the review has been provided by Associate Professor Claude Farah, an adult respiratory and sleep physician at Concord Hospital and Macquarie University Hospital, Sydney.
Please login below to download this issue (PDF)